1stOncology™: Cancer Intelligence Service – Page 15392 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting

On April 25, 2018 Syndax Pharmaceuticals, Inc. ("Syndax," the Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported five poster presentations at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 1-5, 2018 in Chicago, Illinois (Press release, Syndax, APR 25, 2018, View Source [SID1234525705]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation Details
Title: ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors
First Author: Suman Malempati, MD, Oregon Health and Science University
Abstract Number: 10556
Poster Session: Pediatric Oncology
Poster Board: 229
Date and Time: Saturday, June 2, 2018, 8:00-11:30 AM CT, Hall A

Title: ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer
First Author: Nilofer Saba Azad, MD, Sidney Kimmel Cancer Center at Johns Hopkins University
Abstract Number: 3557
Poster Session: Gastrointestinal (Colorectal) Cancer
Poster Board: 50
Date and Time: Sunday, June 3, 2018, 8:00-11:30 AM CT, Hall A

Title: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with nonsmall cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy
First Author: Leena Gandhi, MD, PhD, NYU Perlmutter Cancer Center
Abstract Number: 9036
Poster Session: Lung Cancer—Non-Small Cell Metastatic
Poster Board: 359
Date and Time: Sunday, June 3, 2018, 8:00-11:30 AM CT, Hall A

Title: Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma
First Author: Marina Baretti, MD, Sidney Kimmel Cancer Center at Johns Hopkins University
Abstract Number: TPS4151
Poster Session: Gastrointestinal (Noncolorectal) Cancer
Poster Board: 330a
Date and Time: Sunday, June 3, 2018, 8:00-11:30 AM CT, Hall A

Title: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody
First Author: Sanjiv S. Agarwala, MD, St. Luke’s Hospital
Abstract Number: 9530
Poster Session: Melanoma/Skin Cancers
Poster Board: 357
Date and Time: Monday, June 4, 2018, 1:15-4:45 PM CT, Hall A

Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018

On April 25, 2018 Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) reported that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare Investor Conference on Thursday, May 3rd at 1:30pm EDT (Press release, Aurinia Pharmaceuticals, APR 25, 2018, View Source [SID1234525704]). A webcast will be available and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the site following the event.

Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018

On April 25, 2018 Genomic Health, Inc. (NASDAQ: GHDX) reported that the company will host a conference call and webcast on Wednesday, May 2 at 4:30 p.m. Eastern Time to discuss its first quarter 2018 financial results (Press release, Genomic Health, 25 25, 2018, View Source [SID1234525703]). The call and webcast will follow the release of the first quarter financial results after market close.

Conference Call Details
To access the live conference call on May 2 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada, or +1 (224) 357-2389 internationally. The conference call ID is 2186716. Please dial in approximately ten minutes prior to the start of the call.

To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company’s web site at View Source Please connect to the web site at least 15 minutes prior to the presentation to allow for any software download that may be necessary.

Varian Reports Results for Second Quarter of Fiscal Year 2018

On April 25, 2018 Varian (NYSE: VAR) reported its second quarter fiscal year 2018 results (Press release, Varian Medical Systems, APR 25, 2018, View Source [SID1234525702]).

We are proud of the team’s progress in the second quarter toward executing on our long-term value creation strategy," said Dow Wilson, Chief Executive Officer of Varian. "We continued to strengthen our leadership in radiation therapy and extend our global footprint with the Mobius and Evinance acquisitions. In addition, we are expanding our addressable markets into interventional oncology with the acquisition of Sirtex, expected to close by the end of May."

The company ended the quarter with $740 million in cash and cash equivalents and $255 million of debt. Net cash provided by operating activities was $66 million. During the quarter, the company invested $36 million to repurchase 325,000 shares of common stock.

Oncology Systems Segment
In the fiscal second quarter, Oncology revenues totaled $698 million, up 10 percent in dollars and 6 percent in constant currency. Gross orders were $664 million, up 5 percent in dollars and 1 percent in constant currency. Gross orders in the Americas increased 2 percent in dollars and in constant currency. In EMEA, gross orders rose 11 percent in dollars and were flat in constant currency; in APAC, gross orders increased 3 percent in dollars and 1 percent in constant currency. Operating earnings for the segment increased 16 percent.

Particle Therapy Segment
In the fiscal second quarter, Particle Therapy revenues totaled $32 million, up 2 percent. The company did not book any new ProBeam orders in the quarter.

Acquisition-Related Expenses and Impairment Charges in Q2
Varian’s GAAP net earnings include acquisition-related expenses totaling $20 million for the quarter, primarily driven by $16 million related to hedging the Australian dollar purchase price of the Sirtex acquisition, as well as an impairment charge of $11 million related to the expected refinancing of the Maryland Proton Treatment Center in Baltimore. These costs and the associated tax effects reduced Varian earnings in the second quarter of fiscal 2018 by $0.26 per diluted share on a GAAP basis, and were excluded from non-GAAP results.

FY18 Annual Guidance Updated
Considering the financial and operational performance in the first half and the impact of currency, fiscal year 2018 guidance is updated to the following:

Revenue growth range of 6 percent to 9 percent, which now includes the impact from currency for the remainder of the year
Non-GAAP Operating earnings as a percentage of revenues range of 18 percent to 19 percent
Non-GAAP effective tax rate of 20 percent
Weighted average diluted shares of 93 million
Non-GAAP Earnings per diluted share range of $4.43 to $4.53
Cash flow from operations range of $475 million to $550 million
This updated guidance does not reflect the impact of the Sirtex acquisition, which is expected to close at the end of May.

Please refer to "Discussion of Non-GAAP Financial Measures" below for a description of items excluded from expected non-GAAP earnings.

Investor Conference Call
Varian Medical Systems is scheduled to conduct its second quarter fiscal year 2018 conference call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit the investor relations page on our web site at www.varian.com/investors where it will be archived for a year. To access the call via telephone, dial 1-877-869-3847 from inside the U.S. or 1-201-689-8261 from outside the U.S. The replay can be accessed by dialing 1-877-660-6853 from inside the U.S. or 1-201-612-7415 from outside the U.S. and entering confirmation code 13677574. The telephone replay will be available through 5 p.m. PT, Friday, April 27, 2018.

Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results

On April 25, 2018 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that it will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Wednesday, May 9, 2018 following release of its first quarter 2018 financial results (Press release, Puma Biotechnology, APR 25, 2018, http://investor.pumabiotechnology.com/press-release/puma-biotechnology-host-conference-call-discuss-first-quarter-financial-results [SID1234525699]).

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least ten minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at View Source A replay of the call will be available approximately one hour after completion of the call and will be archived on the Company’s website for 90 days.